China Life Insurance Co. (02628) Report Interpretation

Overview

Goldman Sachs updates China Life forecasts following its 1H26 results and recent equity-market moves. The institution sees stronger investment gains and shareholder distributions, but expects weaker second-half sales to weigh on new business value, leading it to retain Neutral ratings on both share classes.

Core views

Goldman Sachs incorporates China Life's 1H26 results and recent equity-market movements into its FY26-28E forecasts. It raises net-profit estimates by 2-4%, with revised forecasts of Rmb160,355 million for FY26E, Rmb106,997 million for FY27E and Rmb108,281 million for FY28E. The corresponding EPS forecasts are Rmb5.67, Rmb3.79 and Rmb3.83. The report also raises embedded-value estimates by 2-3%, to Rmb1,650,823 million, Rmb1,776,127 million and Rmb1,897,501 million, after reflecting strong investment gains in 1H26. The balance-sheet revision moves in the opposite direction. Goldman Sachs lowers FY26-28E shareholders' equity estimates by 5-6%, citing unrealized equity-investment losses, lower bond yields and liability mark-to-market movements. Revised equity forecasts are Rmb674,544 million in FY26E, Rmb744,639 million in FY27E and Rmb814,129 million in FY28E. Revised ROE is 25.3%, 15.1% and 13.9%, respectively, while the forecast core solvency ratio is 146.4%, 141.7% and 136.8%. On life-insurance operations, the report says 1H26 NBV delivery was in line, but lowers FY26-28E NBV estimates by 4% because it expects lower 2H26 sales amid continuing bancassurance-sales headwinds. The reduction is partly offset by a slight expansion in VONB margin. Revised VONB forecasts are Rmb54,233 million, Rmb56,897 million and Rmb60,137 million for FY26E-FY28E, while FYP forecasts are cut 6% in each year to Rmb246,622 million, Rmb261,791 million and Rmb279,760 million. VONB margin is forecast at 22.0%, 21.7% and 21.5%. Shareholder returns are a relative positive in the update. Following a 50% year-on-year increase in the interim dividend, Goldman Sachs raises FY26-28E DPS estimates by 17-18%. It forecasts FY26E DPS of Rmb1.16 per share, up 36% year on year, followed by Rmb1.22 in FY27E and Rmb1.29 in FY28E. Using a 12-month ROA-based valuation approach, Goldman Sachs raises its H-share target price to HK$32.0 from HK$31.5 and keeps its A-share target at Rmb46.0. These targets imply FY27E P/B multiples of 1.1x for the H shares and 1.8x for the A shares. Based on prices of HK$30.30 and Rmb38.50 as of 31 August 2026, the stated upside is 5.6% for 2628.HK and 19.5% for 601628.SS. Despite the estimate and dividend upgrades, the institution maintains Neutral on both share classes.

Analysis framework

The report updates earnings, balance-sheet, new-business-value, dividend and embedded-value forecasts after 1H26 results and recent equity-market changes. It then applies a 12-month ROA-based target-price framework, with implied FY27E P/B multiples, to assess the H and A shares.

Methodology notes

• Other

  12-month ROA-based target-price methodology

  Goldman Sachs bases its target prices on projected return on assets over a 12-month horizon, with the resulting targets shown alongside implied FY27E price-to-book multiples.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China Life Insurance Co. (H) (2628.HK)

  Primary covered H-share listing; Goldman Sachs maintains Neutral and raises the 12-month target price to HK$32.0.

  Strengths

  Higher earnings, embedded-value and dividend estimates following strong 1H26 investment gains and the interim-dividend increase.

  Weaknesses

  Lower book-value estimates and lower FY26-28E NBV estimates.

  Comparison

  The target implies 1.1x FY27E P/B, versus 1.8x for the A shares.

  Risks

  Investment-market weakness, lower long-term bond yields, weak sales in lower-tier cities and below-peer agent-productivity gains.

• China Life Insurance Co. (A) (601628.SS)

  Primary covered A-share listing; Goldman Sachs maintains Neutral with a 12-month target price of Rmb46.0.

  Strengths

  Higher earnings, embedded-value and dividend estimates following strong 1H26 investment gains and the interim-dividend increase.

  Weaknesses

  Lower book-value estimates and lower FY26-28E NBV estimates.

  Comparison

  The target implies 1.8x FY27E P/B, versus 1.1x for the H shares.

  Risks

  Investment-market weakness, lower long-term bond yields, weak sales in lower-tier cities and below-peer agent-productivity gains.

Key data

• FY26-28E net profit estimate revisions+2% / +4% / +3%Revised to Rmb160,355 million, Rmb106,997 million and Rmb108,281 million.
• FY26-28E shareholders' equity estimate revisions-6% / -5% / -5%Reflects unrealized equity-investment losses, lower bond yields and liability mark-to-market movements.
• FY26-28E VONB estimate revisions-4% / -4% / -4%Lower 2H26 sales assumptions are partly offset by slight VONB-margin expansion.
• FY26E DPSRmb1.16 per shareUp 18% versus the prior estimate and representing 36% year-on-year growth.
• FY26-28E embedded-value estimate revisions+3% / +2% / +2%Revised forecasts are Rmb1,650,823 million, Rmb1,776,127 million and Rmb1,897,501 million.
• H-share target and upsideHK$32.0; 5.6%Versus HK$30.30 closing price on 31 August 2026.
• A-share target and upsideRmb46.0; 19.5%Versus Rmb38.50 closing price on 31 August 2026.

Impact & implications

The report characterizes the update as a balance between stronger investment gains, higher earnings forecasts and materially higher dividend expectations on one hand, and lower book-value and NBV assumptions on the other. This balance supports unchanged Neutral ratings despite the higher H-share target price.

Risks

• Further weakness in investment markets could reduce the solvency ratio and limit China Life's ability to raise dividends.
• A further decline in the 10-year government-bond yield to below 2% is a downside risk.
• Weak insurance-sales growth in lower-tier cities is a risk because China Life has a more dominant market share there.
• Agent-productivity gains below those of peers are a downside risk.
• Stronger A-share performance, sustained double-digit NBV growth, better-than-expected shareholder-return plans or higher long-term bond yields are identified as upside risks.